{"id":"gimeracil","rwe":[{"pmid":"41836238","year":"2026","title":"Development of a second primary tumor during maintenance immunotherapy in metastatic gingival squamous cell carcinoma: a case report.","finding":"","journal":"Frontiers in oncology","studyType":"Clinical Study"},{"pmid":"41803927","year":"2026","title":"Exceptional long-term survival in a patient with recurrent pancreatic carcinoma on adjuvant tegafur-gimeracil-oteracil potassium: a case report.","finding":"","journal":"Journal of medical case reports","studyType":"Clinical Study"},{"pmid":"41766968","year":"2026","title":"Conversion Surgery for Alpha-Fetoprotein-Producing Esophagogastric Junction Cancer with Multiple Liver Metastases and Portal Vein Tumor Thrombus after Nivolumab Combination Chemotherapy: A Case Report and Literature Review.","finding":"","journal":"Surgical case reports","studyType":"Clinical Study"},{"pmid":"41617443","year":"2026","title":"Prognostic Factors and the Impact of Adjuvant S-1 Chemotherapy in Resected Ampulla of Vater Carcinoma: A Single-institution Retrospective Study.","finding":"","journal":"Anticancer research","studyType":"Clinical Study"},{"pmid":"41472492","year":"2026","title":"Real-World Efficacy of Chemotherapy in Patients With Advanced Unresectable Extramammary Paget Disease: A Retrospective Multicenter Study of 138 Japanese Patients.","finding":"","journal":"The Journal of dermatology","studyType":"Clinical Study"}],"tags":[{"label":"gimeracil","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Dihydropyrimidine dehydrogenase [NADP(+)]","category":"target"},{"label":"DPYD","category":"gene"},{"label":"Active","category":"status"},{"label":"HER2negative breast cancer","category":"indication"},{"label":"Hormone receptor pozitive breast cancer","category":"indication"},{"label":"Malignant tumor of stomach","category":"indication"},{"label":"Nordic Group BV","category":"company"}],"phase":"marketed","safety":{"safetySignals":[{"llr":45.156,"date":"","count":12,"signal":"Bone marrow failure","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=45)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Nordic Group BV","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GIMERACIL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:12:42.605904+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:12:48.431344+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:12:42.676959+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GIMERACIL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:12:48.693163+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Dihydropyrimidine dehydrogenase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:12:49.730806+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1730601/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:12:49.379184+00:00"}},"allNames":"gimestat","offLabel":[],"synonyms":["5-chloro-2,4-dihydroxypyridine","gimeracil","gimestat","5-Chloro-4-hydroxy-2-pyridone"],"timeline":[{"date":"1999-03-01","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Taiho Pharmaceutical Co, Ltd)"},{"date":"2011-03-14","type":"positive","source":"DrugCentral","milestone":"EMA approval (Nordic Group BV)"}],"approvals":[{"date":"1999-03-01","orphan":false,"company":"Taiho Pharmaceutical Co, Ltd","regulator":"PMDA"},{"date":"2011-03-14","orphan":false,"company":"Nordic Group BV","regulator":"EMA"}],"brandName":"Gimestat","ecosystem":[{"indication":"HER2negative breast cancer","otherDrugs":[],"globalPrevalence":null},{"indication":"Hormone receptor pozitive breast cancer","otherDrugs":[],"globalPrevalence":null},{"indication":"Malignant tumor of stomach","otherDrugs":[{"name":"capecitabine","slug":"capecitabine","company":"Hoffmann La Roche"},{"name":"docetaxel","slug":"docetaxel","company":"Sanofi Aventis Us"},{"name":"fluorouracil","slug":"fluorouracil","company":"Spectrum Pharms"},{"name":"levofolinic acid","slug":"levofolinic-acid","company":"Spectrum Pharms"}],"globalPrevalence":null}],"mechanism":{"target":"Dihydropyrimidine dehydrogenase [NADP(+)]","targets":[{"gene":"DPYD","source":"DrugCentral","target":"Dihydropyrimidine dehydrogenase [NADP(+)]","protein":"Dihydropyrimidine dehydrogenase [NADP(+)]"}],"modality":"Small Molecule","drugClass":"gimeracil","explanation":"","oneSentence":"","technicalDetail":"Gimestat inhibits dihydropyrimidine dehydrogenase [NADP(+)], the primary enzyme responsible for the catabolism of 5-fluorouracil, thereby increasing its bioavailability and efficacy in treating cancer."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1293","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GIMERACIL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GIMERACIL","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T11:44:59.107863","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:12:51.021815+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"gimeracil","indications":{"approved":[{"name":"HER2negative breast cancer","source":"DrugCentral","snomedId":767444009,"regulator":"FDA"},{"name":"Hormone receptor pozitive breast cancer","source":"DrugCentral","snomedId":417181009,"regulator":"FDA"},{"name":"Malignant tumor of stomach","source":"DrugCentral","snomedId":363349007,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":["Locally Advanced Rectal Carcinoma"],"enrollment":394,"completionDate":"2034-03-02"},{"nctId":"NCT06256328","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2024-01-10","conditions":["Gastric Cancer"],"enrollment":226,"completionDate":"2027-07-31"},{"nctId":"NCT06109779","phase":"PHASE3","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-04","conditions":["Biliary Tract Cancer"],"enrollment":757,"completionDate":"2030-05-03"},{"nctId":"NCT07023315","phase":"PHASE3","title":"A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-08-14","conditions":["Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma"],"enrollment":760,"completionDate":"2031-07"},{"nctId":"NCT05867121","phase":"PHASE1","title":"A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-10-02","conditions":["Non-small Cell Lung Cancer","Gastric Cancer","Pancreatic Ductal Adenocarcinoma"],"enrollment":102,"completionDate":"2026-06-30"},{"nctId":"NCT06808971","phase":"PHASE2","title":"Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-02-28","conditions":["Gastric Adenocarcinoma","Gastro-esophageal Junction Adenocarcinoma"],"enrollment":61,"completionDate":"2027-12-31"},{"nctId":"NCT06761846","phase":"PHASE2","title":"Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-01-17","conditions":["Gastric Adenocarcinoma","Esophagogastric Junction Adenocarcinoma"],"enrollment":70,"completionDate":"2028-12-31"},{"nctId":"NCT07182565","phase":"PHASE1,PHASE2","title":"Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-11-18","conditions":["Gastroesophageal Junction Adenocarcinoma","Hypofractionated Radiotherapy"],"enrollment":84,"completionDate":"2029-08-31"},{"nctId":"NCT07315035","phase":"PHASE2","title":"QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-01-01","conditions":["Gastric Cancer Stage III"],"enrollment":74,"completionDate":"2030-12-31"},{"nctId":"NCT07304258","phase":"PHASE2","title":"A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University","startDate":"2025-12-12","conditions":["Gastric Cancer Peritoneal Metastases"],"enrollment":30,"completionDate":"2027-12-31"},{"nctId":"NCT03013010","phase":"PHASE3","title":"PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy","status":"COMPLETED","sponsor":"Shanghai Cancer Hospital, China","startDate":"2016-12","conditions":["Stomach Neoplasm","GastroEsophageal Cancer","Adenocarcinoma","Locally Advanced Cancer","Chemoradiation"],"enrollment":204,"completionDate":"2024-12-05"},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":["Metastatic Pancreatic Cancer"],"enrollment":320,"completionDate":"2028-06"},{"nctId":"NCT07178340","phase":"PHASE2","title":"Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-09-18","conditions":["Hepatoid Adenocarcinoma of Stomach"],"enrollment":30,"completionDate":"2028-09-20"},{"nctId":"NCT07194005","phase":"PHASE2","title":"Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-09-04","conditions":["Gastric Cancer"],"enrollment":30,"completionDate":"2028-09-30"},{"nctId":"NCT06992362","phase":"PHASE2","title":"Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-05-20","conditions":["Hepatoid Adenocarcinoma of Stomach"],"enrollment":30,"completionDate":"2029-12-31"},{"nctId":"NCT05934331","phase":"PHASE2","title":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","status":"RECRUITING","sponsor":"LaNova Medicines Zhejiang Co., Ltd.","startDate":"2023-07-27","conditions":["Malignant Neoplasms of Digestive Organs"],"enrollment":276,"completionDate":"2028-07-01"},{"nctId":"NCT07007182","phase":"PHASE2","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-10-01","conditions":["Gastric Adenocarcinoma","Stomach Neoplasms"],"enrollment":54,"completionDate":"2030-10-01"},{"nctId":"NCT05149807","phase":"PHASE2,PHASE3","title":"Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer","status":"TERMINATED","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2022-01-26","conditions":["Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer"],"enrollment":81,"completionDate":"2024-04-03"},{"nctId":"NCT03636893","phase":"PHASE2","title":"Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2018-08-24","conditions":["Gastric Cancer","Chemotherapy Effect"],"enrollment":74,"completionDate":"2025-05-08"},{"nctId":"NCT07034742","phase":"EARLY_PHASE1","title":"Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-06-01","conditions":["Gastric Adenocarcinoma"],"enrollment":136,"completionDate":"2028-01-01"},{"nctId":"NCT05161572","phase":"PHASE2","title":"Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer","status":"TERMINATED","sponsor":"Fudan University","startDate":"2021-09-28","conditions":["Stomach Neoplasms","Esophagogastric Junction Disorder","Neoadjuvant Therapy","Chemoradiotherapy","Immunotherapy","Gastrectomy","Adenocarcinoma","Adjuvant Therapy"],"enrollment":6,"completionDate":"2022-09-30"},{"nctId":"NCT05170503","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-12-29","conditions":["Esophagogastric Junction Adenocarcinoma"],"enrollment":37,"completionDate":"2029-01-01"},{"nctId":"NCT04415853","phase":"PHASE3","title":"Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer","status":"RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2021-01-21","conditions":["Esophageal Cancer"],"enrollment":416,"completionDate":"2026-12-30"},{"nctId":"NCT06422858","phase":"PHASE2","title":"Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-05-20","conditions":["Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma"],"enrollment":37,"completionDate":"2026-04"},{"nctId":"NCT06779318","phase":"PHASE4","title":"Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-07","conditions":["Pancreatic Cancer","Postoperative Adjuvant Therapy","Maintenance Therapy"],"enrollment":464,"completionDate":"2028-07"},{"nctId":"NCT04863430","phase":"PHASE2","title":"Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach","status":"WITHDRAWN","sponsor":"Peking University","startDate":"2021-05-11","conditions":["Gastric Cancer"],"enrollment":0,"completionDate":"2023-07-06"},{"nctId":"NCT03662659","phase":"PHASE2","title":"An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-10-16","conditions":["Gastric Cancer","Cancer of the Stomach","Esophagogastric Junction"],"enrollment":274,"completionDate":"2024-01-18"},{"nctId":"NCT06427005","phase":"PHASE2","title":"Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC","status":"RECRUITING","sponsor":"Meng Qiu","startDate":"2023-02-20","conditions":["Fruquintinib","S-1","Raltitrexed"],"enrollment":66,"completionDate":"2026-04-30"},{"nctId":"NCT04260269","phase":"","title":"Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study","status":"ENROLLING_BY_INVITATION","sponsor":"Helsinki University Central Hospital","startDate":"2018-06-01","conditions":["Solid Tumor"],"enrollment":200,"completionDate":"2027-12"},{"nctId":"NCT03252808","phase":"PHASE1","title":"Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takara Bio Inc.","startDate":"2017-09-25","conditions":["Pancreatic Cancer Stage III","Pancreatic Cancer Stage IV"],"enrollment":36,"completionDate":"2035-03-31"},{"nctId":"NCT06662877","phase":"PHASE2,PHASE3","title":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-25","conditions":["Biliary Tract Cancer","Second Line Treatment","Chemotherapy","Tyrosine Kinase Inhibitor"],"enrollment":206,"completionDate":"2029-09-01"},{"nctId":"NCT01285557","phase":"PHASE3","title":"Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2011-04-14","conditions":["Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction"],"enrollment":361,"completionDate":"2014-08-15"},{"nctId":"NCT03175679","phase":"PHASE1","title":"Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC","status":"COMPLETED","sponsor":"Beijing YouAn Hospital","startDate":"2017-04-01","conditions":["Hepatocellular Carcinoma"],"enrollment":10,"completionDate":"2019-03-30"},{"nctId":"NCT04515615","phase":"PHASE2","title":"Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yu jiren","startDate":"2020-09-09","conditions":["Gastric Cancer Stage III"],"enrollment":52,"completionDate":"2026-03-29"},{"nctId":"NCT05144854","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-11-05","conditions":["Gastric Cancer"],"enrollment":626,"completionDate":"2027-05"},{"nctId":"NCT02454062","phase":"PHASE1","title":"A Trial of TAS-114 in Combination With S-1","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2013-03","conditions":["Advanced Solid Tumors"],"enrollment":120,"completionDate":"2017-09-30"},{"nctId":"NCT06487702","phase":"PHASE2","title":"A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Rui-hua Xu, MD, PhD","startDate":"2024-07-10","conditions":["Esophageal Squamous Cell Carcinoma"],"enrollment":70,"completionDate":"2027-06-10"},{"nctId":"NCT05498766","phase":"PHASE4","title":"Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-07-01","conditions":["Gastric Cancer"],"enrollment":702,"completionDate":"2029-11-01"},{"nctId":"NCT04799548","phase":"PHASE2","title":"A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-12-30","conditions":["Advanced Gastric Cancer"],"enrollment":71,"completionDate":"2026-01"},{"nctId":"NCT06385873","phase":"PHASE2","title":"RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-05-01","conditions":["Gastric Cancer/Gastroesophageal Junction Adenocarcinoma"],"enrollment":32,"completionDate":"2028-05-01"},{"nctId":"NCT06368063","phase":"PHASE4","title":"The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Xi'an Jiaotong University","startDate":"2024-05-06","conditions":["Pancreatic Cancer Resectable"],"enrollment":642,"completionDate":"2028-03"},{"nctId":"NCT02746796","phase":"PHASE2,PHASE3","title":"Study of ONO-4538 in Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2016-03","conditions":["Gastric Cancer"],"enrollment":680,"completionDate":"2022-11-17"},{"nctId":"NCT03006705","phase":"PHASE3","title":"Study of Adjuvant ONO-4538 With Resected Gastric Cancer","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2017-01-31","conditions":["Gastric Cancer"],"enrollment":800,"completionDate":"2023-03-31"},{"nctId":"NCT06255379","phase":"PHASE2","title":"Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2024-05-06","conditions":["Metastasis Colorectal Cancer","Colon Cancer","Rectal Cancer"],"enrollment":52,"completionDate":"2027-03-21"},{"nctId":"NCT06187597","phase":"PHASE2","title":"Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":["Locally Advanced Esophageal Squamous Cell Carcinoma"],"enrollment":140,"completionDate":"2028-12-31"},{"nctId":"NCT06194734","phase":"PHASE3","title":"A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer","status":"RECRUITING","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","startDate":"2024-02-05","conditions":["Esophageal Squamous Cell Carcinoma"],"enrollment":490,"completionDate":"2027-12-30"},{"nctId":"NCT05122091","phase":"PHASE2","title":"Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2021-11-05","conditions":["Gastric Cancer","GastroEsophageal Cancer","Fruquintinib","SOX"],"enrollment":53,"completionDate":"2024-11-30"},{"nctId":"NCT04694183","phase":"PHASE2","title":"The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Quan Wang","startDate":"2020-08-17","conditions":["Stomach Neoplasms"],"enrollment":37,"completionDate":"2023-05-06"},{"nctId":"NCT01515748","phase":"PHASE3","title":"Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-12-30","conditions":["Gastric Cancer"],"enrollment":530,"completionDate":"2021-12-13"},{"nctId":"NCT05960955","phase":"PHASE2","title":"Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2023-11-13","conditions":["Resectable Gastric or Gastroesophageal Junction Adenocarcinoma"],"enrollment":90,"completionDate":"2027-11-30"},{"nctId":"NCT06123455","phase":"PHASE2","title":"Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Tang-Du Hospital","startDate":"2023-08-01","conditions":["Gastric Cancer"],"enrollment":60,"completionDate":"2025-07-31"},{"nctId":"NCT03267121","phase":"PHASE2","title":"A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2017-10-01","conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":38,"completionDate":"2020-11-01"},{"nctId":"NCT04267549","phase":"PHASE2","title":"Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-05-01","conditions":["Gastric Cancer Stage IV"],"enrollment":47,"completionDate":"2023-08-30"},{"nctId":"NCT01845337","phase":"PHASE2","title":"Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2014-02-05","conditions":["Gastrointestinal Cancer","Cancer of Unknown Primary Site","Pancreatic Cancer","Bile Duct Neoplasms"],"enrollment":59,"completionDate":"2020-10-08"},{"nctId":"NCT05813015","phase":"PHASE3","title":"Study of Comparing of With and Without Sequential Therapy of S-1","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2023-01-28","conditions":["Locally Advanced Gastric Adenocarcinoma","Chemotherapy Effect"],"enrollment":70,"completionDate":"2026-12-31"},{"nctId":"NCT05774964","phase":"PHASE2","title":"Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2023-03-15","conditions":["For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method"],"enrollment":100,"completionDate":"2025-03-15"},{"nctId":"NCT05769725","phase":"PHASE2","title":"A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-03-01","conditions":["Serplulimab,Gastric Cancer, Adjuvant Therapy"],"enrollment":70,"completionDate":"2026-03-31"},{"nctId":"NCT02191566","phase":"PHASE2","title":"S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy","status":"TERMINATED","sponsor":"Kangbuk Samsung Hospital","startDate":"2015-05","conditions":["Stomach Cancer"],"enrollment":8,"completionDate":"2019-10"},{"nctId":"NCT05627414","phase":"PHASE2","title":"Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-01-01","conditions":["Gastric Cancer"],"enrollment":30,"completionDate":"2025-01-01"},{"nctId":"NCT05529355","phase":"PHASE2","title":"Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Anhui Chest Hospital","startDate":"2022-09-18","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":45,"completionDate":"2023-09-18"},{"nctId":"NCT05468138","phase":"PHASE2","title":"PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-08-25","conditions":["MSI-H","PD-1 Immunotherapy","Gastric Cancer","Adjuvant Therapy"],"enrollment":141,"completionDate":"2025-12-31"},{"nctId":"NCT02749526","phase":"PHASE2","title":"Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial","status":"TERMINATED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-04","conditions":["Esophageal"],"enrollment":70,"completionDate":"2018-12"},{"nctId":"NCT05396326","phase":"PHASE1","title":"A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-06-01","conditions":["Gastric Cancer"],"enrollment":20,"completionDate":"2025-12-31"},{"nctId":"NCT05346874","phase":"PHASE2","title":"Neoadjuvant TACiE in Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-06-01","conditions":["Gastric Cancer"],"enrollment":37,"completionDate":"2025-05-01"},{"nctId":"NCT05216237","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer","status":"UNKNOWN","sponsor":"Jiuda Zhao","startDate":"2022-02-15","conditions":["Gastric Cancer","Chemotherapy","Immunotherapy"],"enrollment":31,"completionDate":"2025-06-01"},{"nctId":"NCT05228743","phase":"NA","title":"Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2020-09-01","conditions":["Gastric Cancer"],"enrollment":180,"completionDate":"2023-10-31"},{"nctId":"NCT05095467","phase":"PHASE2","title":"HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction","status":"NOT_YET_RECRUITING","sponsor":"Xuefei.Wang","startDate":"2021-10","conditions":["Stomach Neoplasms","Peritoneal Metastases"],"enrollment":157,"completionDate":"2026-10"},{"nctId":"NCT04997837","phase":"PHASE3","title":"Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-07-21","conditions":["Gastric Cancer"],"enrollment":433,"completionDate":"2027-10-21"},{"nctId":"NCT04384601","phase":"PHASE3","title":"Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2021-09","conditions":["Gastric Cancer","Neoadjuvant Chemotherapy"],"enrollment":246,"completionDate":"2027-09"},{"nctId":"NCT03904225","phase":"PHASE2","title":"Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2018-12-14","conditions":["Nasopharyngeal Carcinoma"],"enrollment":220,"completionDate":"2022-12"},{"nctId":"NCT02564367","phase":"PHASE1,PHASE2","title":"Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2015-10-06","conditions":["Adenocarcinoma,Stomach","Adenocarcinoma, Esophagogastric Junction"],"enrollment":30,"completionDate":"2020-03-06"},{"nctId":"NCT02128243","phase":"PHASE2","title":"Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-09","conditions":["Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction","Gastric Neoplasm","Gastroesophageal Junction Adenocarcinoma","Esophageal Adenocarcinoma","Gastric Adenocarcinoma","Esophageal Neoplasms"],"enrollment":242,"completionDate":"2020-10-08"},{"nctId":"NCT03415802","phase":"PHASE2","title":"Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Aiping Zhou","startDate":"2015-05-11","conditions":["Advanced Pancreatic Cancer"],"enrollment":32,"completionDate":"2019-07-11"},{"nctId":"NCT03585062","phase":"PHASE2","title":"Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer","status":"TERMINATED","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2017-11-20","conditions":["Pancreatic Cancer","Neoadjuvant Chemotherapy"],"enrollment":40,"completionDate":"2019-07-01"},{"nctId":"NCT04677673","phase":"PHASE2,PHASE3","title":"Neoadjuvant Chemotherapy Plus Surgery Versus Surgery First For Elderly Gastric Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"BIRENDRA KUMAR SAH","startDate":"2021-01","conditions":["Gastric Cancer","Chemotherapy Effect","Elderly Patients","Surgery"],"enrollment":232,"completionDate":"2027-01"},{"nctId":"NCT04571489","phase":"PHASE2","title":"A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2020-12-01","conditions":["Pancreatic Cancer"],"enrollment":60,"completionDate":"2023-12-01"},{"nctId":"NCT00429858","phase":"PHASE2","title":"Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Andrew Ko","startDate":"2007-01-22","conditions":["Pancreatic Cancer"],"enrollment":21,"completionDate":"2010-01-20"},{"nctId":"NCT04410887","phase":"PHASE1,PHASE2","title":"Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC)","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2020-12","conditions":["Stomach Cancer","Gastric Cancer"],"enrollment":30,"completionDate":"2022-03"},{"nctId":"NCT04377048","phase":"PHASE2","title":"Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2020-07-01","conditions":["Stage IV Pancreatic Cancer"],"enrollment":38,"completionDate":"2022-12-31"},{"nctId":"NCT04152889","phase":"PHASE2","title":"A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-04-14","conditions":["Gastric Cancer Stage III"],"enrollment":20,"completionDate":"2022-12"},{"nctId":"NCT04345770","phase":"PHASE2","title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Wuhan University","startDate":"2020-04-01","conditions":["Malignant Neoplasm of Stomach"],"enrollment":100,"completionDate":"2025-05-31"},{"nctId":"NCT03002831","phase":"PHASE2","title":"Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer","status":"TERMINATED","sponsor":"Henan Cancer Hospital","startDate":"2016-11","conditions":["Advanced Cancer"],"enrollment":13,"completionDate":"2019-10"},{"nctId":"NCT02528110","phase":"PHASE2","title":"Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Wuhan University","startDate":"2015-08","conditions":["Malignant Neoplasm of Stomach"],"enrollment":100,"completionDate":"2020-03-10"},{"nctId":"NCT04310774","phase":"PHASE1,PHASE2","title":"CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2020-04-15","conditions":["Cervical Cancer","Chemotherapy"],"enrollment":200,"completionDate":"2026-04-15"},{"nctId":"NCT03448549","phase":"PHASE3","title":"SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2018-01-01","conditions":["Colorectal Cancer Stage III","Adjuvant Chemotherapy"],"enrollment":1191,"completionDate":"2024-01-01"},{"nctId":"NCT01516944","phase":"PHASE2,PHASE3","title":"Perioperative Chemotherapy for Potentially Resectable Gastric Cancer","status":"COMPLETED","sponsor":"Hebei Medical University","startDate":"2012-02","conditions":["Gastric Cancer"],"enrollment":749,"completionDate":"2018-12"},{"nctId":"NCT03192735","phase":"PHASE2","title":"Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Chang-Ming Huang, Prof.","startDate":"2017-09-01","conditions":["Apatinib Combined","SOX","Neoadjuvant Therapy","Locally Advanced Gastric Cancer"],"enrollment":50,"completionDate":"2024-12-11"},{"nctId":"NCT04202484","phase":"PHASE2","title":"Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-02-01","conditions":["Gastric Cancer"],"enrollment":20,"completionDate":"2023-02-01"},{"nctId":"NCT03129256","phase":"PHASE2","title":"An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Changzhou Cancer Hospital of Soochow University","startDate":"2016-12-01","conditions":["Non-small Cell Lung Cancer"],"enrollment":52,"completionDate":"2018-12-30"},{"nctId":"NCT02347904","phase":"PHASE1","title":"Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2014-12","conditions":["Esophageal Cancer"],"enrollment":40,"completionDate":"2019-11"},{"nctId":"NCT03990103","phase":"PHASE2","title":"S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2017-11-01","conditions":["Metastatic Gastric Adenocarcinoma"],"enrollment":66,"completionDate":"2022-04-30"},{"nctId":"NCT03941561","phase":"PHASE3","title":"S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）","status":"RECRUITING","sponsor":"Fudan University","startDate":"2019-01-01","conditions":["Gastric Cancer"],"enrollment":1006,"completionDate":"2027-05-01"},{"nctId":"NCT03825328","phase":"PHASE2","title":"A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )","status":"UNKNOWN","sponsor":"Yanqiao Zhang","startDate":"2019-01-30","conditions":["Pancreatic Cancer"],"enrollment":30,"completionDate":"2020-12-30"},{"nctId":"NCT03700333","phase":"PHASE3","title":"Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2018-10-20","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":120,"completionDate":"2019-10-20"},{"nctId":"NCT03096184","phase":"PHASE2","title":"A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers","status":"UNKNOWN","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2016-12-23","conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":38,"completionDate":"2019-05-01"},{"nctId":"NCT02216149","phase":"PHASE2","title":"Effects of S-1 and Capecitabine on Coronary Artery Blood Flow","status":"TERMINATED","sponsor":"Heikki Joensuu","startDate":"2015-01","conditions":["Esophagus Cancer","Stomach Cancer","Small Bowel Cancer","Colon Cancer","Rectum Cancer"],"enrollment":20,"completionDate":"2018-08"},{"nctId":"NCT03601156","phase":"NA","title":"Preoperative Intraarterial Chemoembolization Combined With Radiotherpy in Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"Third Military Medical University","startDate":"2014-06","conditions":["Rectal Cancer"],"enrollment":204,"completionDate":"2020-11"},{"nctId":"NCT03475615","phase":"PHASE3","title":"A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2018-03-16","conditions":["Gastric Cancer","Stomach Neoplasms"],"enrollment":215,"completionDate":"2020-12-31"},{"nctId":"NCT01918852","phase":"PHASE3","title":"S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2013-12","conditions":["Colorectal Cancer","Metastases"],"enrollment":161,"completionDate":"2018-03"},{"nctId":"NCT02359058","phase":"PHASE1","title":"A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-02","conditions":["Stomach Neoplasms"],"enrollment":18,"completionDate":"2016-11"}],"_emaApprovals":[{"date":"2011-03-14","status":"Authorised","company":"Nordic Group BV"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"013264","UNII":"UA8SE1325T","CHEBI":"CHEBI:31652","INN_ID":"7728","UMLSCUI":"C0535459","chemblId":"CHEMBL1730601","ChEMBL_ID":"CHEMBL1730601","KEGG_DRUG":"D01846","DRUGBANK_ID":"DB09257","PUBCHEM_CID":"54679224","SNOMEDCT_US":"712518000","MESH_SUPPLEMENTAL_RECORD_UI":"C104201"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Nordic Group BV","relationship":"Original Developer"},{"period":"1999","companyName":"Taiho Pharmaceutical Co, Ltd","relationship":"PMDA Licensee"}],"publicationCount":442,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"originalDeveloper":"Nordic Group BV","recentPublications":[{"date":"2026","pmid":"41836238","title":"Development of a second primary tumor during maintenance immunotherapy in metastatic gingival squamous cell carcinoma: a case report.","journal":"Frontiers in oncology"},{"date":"2026 Mar 9","pmid":"41803927","title":"Exceptional long-term survival in a patient with recurrent pancreatic carcinoma on adjuvant tegafur-gimeracil-oteracil potassium: a case report.","journal":"Journal of medical case reports"},{"date":"2026","pmid":"41766968","title":"Conversion Surgery for Alpha-Fetoprotein-Producing Esophagogastric Junction Cancer with Multiple Liver Metastases and Portal Vein Tumor Thrombus after Nivolumab Combination Chemotherapy: A Case Report and Literature Review.","journal":"Surgical case reports"},{"date":"2026 Feb","pmid":"41617443","title":"Prognostic Factors and the Impact of Adjuvant S-1 Chemotherapy in Resected Ampulla of Vater Carcinoma: A Single-institution Retrospective Study.","journal":"Anticancer research"},{"date":"2026 Mar","pmid":"41472492","title":"Real-World Efficacy of Chemotherapy in Patients With Advanced Unresectable Extramammary Paget Disease: A Retrospective Multicenter Study of 138 Japanese Patients.","journal":"The Journal of dermatology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Nordic Group BV","companyId":"nordic-group-bv","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"1999-03-01T00:00:00.000Z","mah":"Taiho Pharmaceutical Co, Ltd","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:12:51.021815+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}